Status
Completed
Phase
N/A
Study type
Observational
Enrollment
105
Sex
Women only
Ages
Up to 55 Years
Primary completion
2025-05-15
Last update
2025-11-18

What this trial studies

This study investigates the relationship between temperament traits and menopausal symptoms using the TEMPS-A and MRS scales in women at menopausal transition stages. It is a cross-sectional observational study.

Conditions in scope

  • Menopause
  • Personality
  • Temperament

Interventions

  • Not specified in the public record.

Who can join

Women only · Up to 55 Years · Accepts healthy volunteers.

Inclusion criteria

  • Women classified as STRAW stages -1, +1a, and +1b (menopausal transition stages)
  • Ability to complete questionnaires and provide informed consent

Exclusion criteria

  • History of hormone therapy during the past 6 months
  • History of surgical menopause (bilateral oophorectomy)
  • Presence of severe physical disorders (e.g., malignancy, severe cardiovascular diseases)
  • Presence of severe psychological disorders (e.g., major depressive disorder, psychosis)

Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.

Where it’s happening

CityState / RegionFacilitySite status
Istanbul Bağcılar Training and Reserach Hospital Unknown

Status & timeline

  • Overall status: Completed
  • Study type: Observational
  • Phase: N/A
  • Start date: 2024-01-01
  • Primary completion: 2025-05-15
  • Last update posted: 2025-11-18
  • First posted: 2025-05-15

Lead sponsor: Bagcilar Training and Research Hospital (Other Gov)

For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.

Outcome measures

Primary outcomes

  • TEMPS-A Depressive Subscale Score at Baseline (Baseline (single time point at enrollment))
    Score from the depressive subscale of the TEMPS-A questionnaire, assessing baseline depressive temperament
  • TEMPS-A Cyclothymic Subscale Score at Baseline (Baseline (single time point at enrollment))
    Score from the cyclothymic subscale of the TEMPS-A questionnaire, assessing mood instability.
  • TEMPS-A Hyperthymic Subscale Score at Baseline (Baseline (single time point at enrollment))
    Score from the hyperthymic subscale of the TEMPS-A questionnaire, assessing elevated or overly positive mood tendencies.
  • TEMPS-A Irritable Subscale Score at Baseline (Baseline (single time point at enrollment))
    Score from the irritable subscale of the TEMPS-A questionnaire, assessing baseline tendency toward irritability.
  • TEMPS-A Anxious Subscale Score at Baseline (Baseline (single time point at enrollment))
    Score from the anxious subscale of the TEMPS-A questionnaire, assessing trait anxiety.

If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.

Important. Information from ClinicalTrials.gov as of May 8, 2026. Trial details (status, sites, contacts, eligibility, outcomes) change frequently — always check the official record at https://clinicaltrials.gov/study/NCT06972290 before contacting a site.

ClearedRx is not affiliated with this trial or its sponsor. We index public-domain ClinicalTrials.gov records to help patients find evidence-based context for menopause care decisions. ClearedRx itself is a telehealth menopause/HRT brand — we do not enroll patients in trials.